Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Worldwide demand for immunity products has accelerated in recent months due to coronavirus. This trend is likely to deliver a 'new norm' of higher growth, says SIRIO Europe (Ayanda) — the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO).

Demand for immunity products to be sustained long-term says SIRIO

Europe has already seen a significant spike in the demand for immunity products across the main economies. Recent weekly data from Euromonitor show an increased purchasing of vitamin C and multivitamins by consumers, with unusual levels of stockouts present throughout Europe.

During lockdowns, production and supply chains have been fairly robust, but there have still been large stock shortages. This is surprising given that we are approaching summer, which is not traditionally a peak period for these products. Anticipating a surge, Dr Dominique Baum, Managing Director at SIRIO Europe (Ayanda), advised that the company has secured a "very large inventory of ingredients to ensure continuity of supply" for all its customers.

In addition, confinement regulations have left consumers with reduced exposure to sunlight which, in turn, has increased sales of nutraceuticals containing vitamin D or other ingredients that compensate for the lack of natural daylight.

Also proving popular among consumers are products that strengthen their respiratory and cardiovascular systems, with omega-3 fatty acids and antioxidants (that may protect against oxidative stress). The company suggests the long-term cumulative effect will be continued growth in health-boosting and immune-boosting supplements, adding a further driver to an already expanding nutraceuticals class.

“The lasting impact of the virus will see a further acceleration of an already popular product class and, in the next few years, we will likely see many new innovative immune formulations delivered via softgels and gummies. Consumers will be looking for new ways to potentially boost health and immunity with combination products, and we anticipate those products with multiple actives are likely to be increasingly popular. It’s a difficult time for society, but it could lead to further improvements with an increased consumer focus on wellbeing,” said Dr Baum.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
AbbVie completes Allergan acquisition

AbbVie completes Allergan acquisition

11 May 2020

Creates biopharmaceutical company with leadership positions in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.

Read more